Harmony Biosciences(HRMY) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - In Q4 2025, Harmony Biosciences reported net product revenue of $243.8 million, a 21% increase from $201.3 million in Q4 2024, marking the highest quarterly revenues to date [3][22] - For the full year 2025, WAKIX generated $868.5 million in net product revenue, continuing six consecutive years of revenue growth and profitability [4] - Non-GAAP adjusted net income for Q4 2025 was $33.4 million, or $0.57 per diluted share, compared to $64.2 million, or $1.10 per diluted share in the prior quarter [23] Business Line Data and Key Metrics Changes - WAKIX achieved approximately 400-plus average patient adds for three consecutive quarters, reaching about 8,500 average patients on the drug [3][4] - The company anticipates WAKIX net revenue to reach blockbuster status of $1 billion-$1.04 billion in 2026, driven by strong demand and market opportunity [4][10] Market Data and Key Metrics Changes - There are approximately 80,000 diagnosed patients with narcolepsy, indicating a significant market opportunity for continued growth of WAKIX [4] - The recent FDA approval of WAKIX for treating cataplexy in pediatric patients aged 6 years and older is expected to enhance market penetration [10][95] Company Strategy and Development Direction - Harmony is focused on extending the WAKIX franchise with the upcoming NDA submission for Pitolisant GR in Q2 2026 and a target PDUFA date in Q1 2027 [5][26] - The company is also exploring broader CNS indications with a new formulation of pitolisant, supported by newly licensed IP with patent protection until 2042 [6][17] - A robust late-stage pipeline with five ongoing Phase 3 registrational trials across distinct CNS indications is in place, setting the stage for multiple catalysts [7][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving blockbuster status for WAKIX in 2026, citing strong execution and market demand [4][26] - The company is well-positioned with a strong balance sheet, approximately $882.5 million in cash equivalents, to fund growth and pipeline advancements [22][24] Other Important Information - The company has settled with six of the seven ANDA filers regarding WAKIX, with generic entry not expected before March 2030 if pediatric exclusivity is granted [5][50] - Significant increases in R&D investments are anticipated as the company advances its pipeline, with five registrational studies ongoing and a sixth planned [25][63] Q&A Session Summary Question: Can you comment on the baseline seizure rates and the emerging benefit-risk profile for EPX-100? - Management noted that patients in the Dravet syndrome study had treatment-resistant seizures, with a median reduction in seizures of approximately 50% and a favorable safety profile compared to other medications [30][32] Question: What is the PK, PD, and safety bar for the orexin 2 receptor agonist? - Management indicated that they expect to see clinical PK data by mid-2026 and are making progress towards advancing the program to the next stage of development [39][41] Question: Can you clarify the increase in SG&A expenses in Q4? - The increase was primarily driven by R&D investments for Phase 3 studies and litigation expenses related to ANDA settlements [62][63] Question: What is the timeline for decisions regarding ongoing litigation? - Management stated that the timeline for a ruling is uncertain, but they remain confident in their IP strength and the settlements achieved with generic filers [78][79]